hepatitis C

FDA panel backs Gilead Sciences' hepatitis C drug
Yahoo/AP
Sat, 10/26/13 - 08:07 am
Gilead
FDA
advisory panels
hepatitis C
sofosbuvir
J&J-Medivir Hepatitis C Pills Wins U.S. Panel Backing
Bloomberg
Thu, 10/24/13 - 06:04 pm
FDA
JNJ
Medivir
hepatitis C
simeprevir
The Most Important Week of the Year Has Arrived for Gilead Sciences
Motley Fool
Wed, 10/23/13 - 08:24 am
Gilead
sofosbuvir
hepatitis C
J&J-Medivir’s Drug Works Against Hepatitis C
Bloomberg
Tue, 10/22/13 - 08:36 am
JNJ
Medivir
hepatitis C
simeprevir
FDA
J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail
Fierce Biotech
Tue, 10/8/13 - 09:41 am
JNJ
NS5A Inhibitors
GSK
hepatitis C
simeprevir
GSK2336805
Achillion Falls on FDA Hold on Hepatitis C Medicine
Bloomberg
Mon, 09/30/13 - 10:47 am
Achillion
FDA
hepatitis C
sovaprevir
These 2 Hepatitis-C Drug Developers Are Getting Left in the Dust
Motley Fool
Mon, 09/30/13 - 10:41 am
hepatitis C
Vertex Pharmaceuticals
Incivek
sovaprevir
Achillion
IDX184
IDX320
Idenix
Twitter Trounces Wall St. With Real-Time Take on Achillion Pharma's Hep C News
The Street
Sun, 09/29/13 - 01:36 pm
twitter
Achillion
hepatitis C
3 Companies Racing to Transform Hepatitis-C Treatment
Motley Fool
Thu, 09/19/13 - 02:58 am
hepatitis C
Gilead
sofosbuvir
AbbVie
Bristol-Myers Squibb
daclatasvir
asunaprevir
BMS-791325
3 Drug Classes That May Become Obsolete Within 3 Years
Motley Fool
Sun, 09/15/13 - 12:26 pm
interferon
hepatitis C
type 2 diabetes
dialysis
Gilead's sofosbuvir cures some of the toughest hepatitis C cases
Fierce Biotech
Wed, 08/28/13 - 12:38 pm
hepatitis C
Gilead
sofosbuvir
[video] Biotech's Next Big Thing: Fall Trials
TheStreet.com
Fri, 08/23/13 - 10:20 am
clinical trials
Biodel
Coronado Biosciences
Achillion
BIOD-531
hepatitis C
pig whip worms
Vertex: Risk-Reward Less Favorable If HCV Pipeline Is In Question
Seeking Alpha
Mon, 07/29/13 - 01:34 pm
Vertex Pharmaceuticals
hepatitis C
VX-135
Vertex Says U.S. Places Partial Hold on Hepatitis Study
Bloomberg
Sat, 07/27/13 - 11:09 am
Vertex Pharmaceuticals
VX-135
hepatitis
hepatitis C
Vertex Says U.S. Places Partial Hold on Hepatitis Study
Bloomberg
Thu, 07/25/13 - 05:27 pm
Vertex Pharmaceuticals
VX-135
hepatitis C
Three Future Winners and One Major Loser in the HCV Wars
Motley Fool
Sat, 07/20/13 - 11:26 am
Gilead Sciences
AbbVie
hepatitis
hepatitis C
Bristol-Myers Squibb
Idenix
Three Future Winners and One Major Loser in the HCV Wars
Motley Fool
Fri, 07/19/13 - 11:38 am
hepatitis C
AbbVie
Bristol-Myers Squibb
Gilead
Idenix
sofosbuvir
ledipasvir
daclatasvir
asunaprevir
BMS-791325
IDX20963
Achillion Hepatitis C Drug Trial on Hold on Liver Concern
Bloomberg
Tue, 07/2/13 - 01:25 am
Achillion
hepatitis C
sovaprevir
Achillion May Be The Most Underrated Biotech Left
Seeking Alpha
Wed, 06/26/13 - 09:35 am
Achillion
AbbVie
Bristol-Myers Squibb
Gilead
Vertex Pharmaceuticals
Indenix
ACH-3102
ACH-1625
hepatitis C
This Week in Biotech
Motley Fool
Sun, 06/23/13 - 11:11 am
Nektar
NKTR-181
pain management
Novartis
serelaxin
Idenix
IDX20963
hepatitis C
ViroPharma
JNJ
Aragon
ARN-509
prostage cancer

Pages